You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Michael J. Fox Foundation-led project aims to lead researchers to new insights about biomarkers indicating Parkinson's disease progression.
The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1.
The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.
Investigators identified dozens of Alzheimer's-related epigenetic signatures based on cytosine methylation and other profiles in Alzheimer's-related cell lines and patient samples.
The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
The longtime quest of one Microsoft data scientist to stop infant crib deaths has grown into a genomics and AI research program with lofty goals.
The firm said that with the approval, the firm's liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test is now available in every state.
The TATTON study found a combination therapy could treat some EGFR-positive lung cancer patients who developed MET-based resistance, but the best way to gauge MET status isn't yet clear.
The MammaSeq assay comprises 79 genes and 1,369 mutations in breast cancer that could be used as potential downstream therapeutic targets.
OncoDNA anticipates a strong increase in the use of OncoDNA profiling products in Europe with the partnerships with Gammaray and AMS.
The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.
According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.
The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.
In Nature this week: the largest known collection of human genetic variants, and more.